Overview :
CSIR-CCMB has developed ISS1 and ISS2, India-specific tools to assess sickle cell anaemia severity. Know the study, scores, PSS comparison and exam facts.
CSIR-CCMB Develops
Scientists at CSIR-Centre for Cellular and Molecular Biology (CCMB) developed India-specific tools to assess the severity of sickle cell anaemia. The study used clinical data from 171 Indian children up to 18 years old treated at Government Medical College and Hospital, Nagpur.
What Is Sickle Cell Anaemia?
Sickle cell anaemia is an inherited blood disorder. It affects haemoglobin, the protein that carries oxygen in blood. Patients may face anaemia, pain attacks and problems in different organs. Its effects can vary between populations.
India-Specific Score
Scientists developed two tools called ISS1 and ISS2 . ISS means India-specific Severity Score . ISS1 reached nearly 83% accuracy in clinical assessment. ISS2 used simple clinical signs instead of laboratory tests and showed about 85% concordance with expert assessment.
Why ISS2 Matters
ISS2 correctly identified all patients in the mild category. Doctors can use visible clinical signs with this model. It may help them make treatment decisions when detailed laboratory tests are not easily available.
Comparison with PSS
The Paediatric Severity Score (PSS) is an international tool used to assess sickle cell disease severity. In the Indian study, PSS matched expert assessments in about 67% of cases . Researchers found that international scores may not fully reflect the disease pattern seen among Indian patients.
CSIR Sickle Cell Mission
The work forms part of the CSIR-Sickle Cell Anaemia Mission . The mission also includes an affordable PCR-based molecular test developed by CSIR-CCMB. The test received validation from the Indian Council of Medical Research and showed 100% sensitivity and specificity , according to the given source.
Hydroxyurea and Treatment
Hydroxyurea is a medicine used in sickle cell disease management. It can help reduce complications. Severity scores can give doctors another clinical tool to understand a patient's condition and plan care.
Need for More Validation
Researchers need to test ISS1 and ISS2 in larger and more diverse groups before wider use. The tools may also help other low- and middle-income countries with similar patient and healthcare settings.
Exam-Focused Points :
- Research body: CSIR-Centre for Cellular and Molecular Biology (CCMB).
- Disease: Sickle cell anaemia.
- Study group: 171 Indian children up to 18 years.
- India-specific tools: ISS1 and ISS2.
- ISS1 accuracy: Nearly 83%.
- ISS2 concordance: About 85%.
- International score compared: Paediatric Severity Score (PSS).
FAQs :
1. What did CSIR-CCMB develop?
It developed India-specific severity scores for sickle cell anaemia.
2. What are ISS1 and ISS2?
They are India-specific tools for assessing sickle cell disease severity.
3. How many children provided data for the study?
The study used clinical data from 171 Indian children.
4. Which international score was compared?
Researchers compared the tools with the Paediatric Severity Score, or PSS.
5. Why is ISS2 useful?
ISS2 uses observable clinical indicators and can support assessment without extensive laboratory tests.